Primary melanoma of the cervix uteri: a systematic review and meta-analysis of the reported cases
File(s)
Published version
Author(s)
Kechagias, Konstantinos S
Zafeiri, Marina
Triantafyllidis, Konstantinos Katsikas
Kyrtsonis, Georgios
Geropoulos, Georgios
Type
Journal Article
Abstract
Primary malignant melanoma (MM) of the cervix uteri is a rare and aggressive malignancy of the female reproductive tract. Considering that clinical data on this cancer are scarce, we aimed to comprehensively examine the currently available literature and provide an overview of the reported cases of cervical MM focusing on the clinical characteristics, diagnosis and therapeutic management. We conducted a systematic review of the literature by screening three electronic databases until June 2022. The critical appraisal checklist provided by the Joanna Briggs Institute was employed to evaluate the overall quality of the studies. We included 96 reports, which comprised 137 patients diagnosed with MM of the cervix. The mean age of the patients was 56.5 (median: 58, age range: 33–88). Data regarding menopausal status were provided for 98 patients with 15 being premenopausal and 83 being postmenopausal. The most common presenting symptom was vaginal bleeding (83%, 100/121). Biopsy (either excisional or punch biopsy) was used as the first diagnostic modality in most of the patients (67%, 64/95), followed by cytology (18%, 17/95). In 74 cases, the FIGO staging system for cervical cancer was used with the most common stage being FIGO stage I (38%, 28/74), followed by FIGO stage II (36%, 27/74), FIGO stage III (19%, 14/74) and FIGO stage IV (7%, 5/74). Most of the patients were managed surgically (90%, 119/131) with a hysterectomy (either radical or total), and a salpingo-oophorectomy with/without lymphadenectomy was the most common approach utilized (40%, 48/119). The data of clinical outcomes were provided for 105 patients, of whom 61 died (58%, 61/105) and 44 survived (42%, 44/105). Knowledge regarding the rare occurrence of MM in the cervix and the increased awareness of clinicians can prevent clinical misdiagnosis and ultimately improve further the clinical outcomes of patients developing this rare malignancy.
Date Issued
2023-03-01
Date Acceptance
2023-02-27
Citation
Biology, 2023, 12 (3)
ISSN
2079-7737
Publisher
MDPI
Journal / Book Title
Biology
Volume
12
Issue
3
Copyright Statement
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).
License URL
Identifier
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000954190900001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
Subjects
AMELANOTIC MELANOMA
Biology
BLUE NEVUS
CANCER
cervical cancer
cervix uteri
CYTOLOGY
FEMALE GENITAL-TRACT
gynecological malignancy
Life Sciences & Biomedicine
Life Sciences & Biomedicine - Other Topics
melanoma
melanosis
MUCOSAL MELANOMAS
PRIMARY MALIGNANT-MELANOMA
RADIATION
Science & Technology
Publication Status
Published
Coverage Spatial
Switzerland
Article Number
398
Date Publish Online
2023-03-02